Genetic polymorphisms in Toll-like receptor 3 gene are associated with the risk of hepatitis B virus-related liver diseases in a Chinese population

Gene

Volumn 569, Issue 2, 2015, Pages 218-224

  Huang, Xiamei ^a   Li, Haiwei ^a   Wang, Jian ^a   Huang, Chunni ^a   Lu, Yu ^a   Qin, Xue ^a   Li, Shan ^a  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Chronic hepatitis B; Hepatocellular carcinoma; Liver cirrhosis; Polymorphism; Toll like receptor 3

Indexed keywords

TOLL LIKE RECEPTOR 3;

ADULT; ARTICLE; CHRONIC HEPATITIS B; CONTROLLED STUDY; DISEASE PREDISPOSITION; DNA POLYMORPHISM; DNA SEQUENCE; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; ASIAN CONTINENTAL ANCESTRY GROUP; COMPLICATION; GENETIC PREDISPOSITION; GENETICS; HEPATITIS B; LIVER TUMOR; VIROLOGY;

HEPATITIS B VIRUS;

ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, HEPATOCELLULAR; GENETIC PREDISPOSITION TO DISEASE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; TOLL-LIKE RECEPTOR 3;

EID: 84937973355     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2015.05.054     Document Type: Article

References (45)

1. Akira S. Pathogen recognition by innate immunity and its signaling. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 2009, 85:143-156.
2. Alexopoulou L., Holt A.C., Medzhitov R., Flavell R.A. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001, 413:732-738.
3. Al-Qahtani A., Al-Ahdal M., Abdo A., Sanai F., Al-Anazi M., Khalaf N., Viswan N.A., Al-Ashgar H., Al-Humaidan H., Al-Suwayeh R., Hussain Z., Alarifi S., Al-Okail M., Almajhdi F.N. Toll-like receptor 3 polymorphism and its association with hepatitis B virus infection in Saudi Arabian patients. J. Med. Virol. 2012, 84:1353-1359.
4. Baldissera V.D., de Mattos A.A., Coral G.P., de Araujo F.B., Marroni C.A., de Mello Brandao A.B., Ott Fontes P.R., Schmidt Cerski C.T., Hartmann A.A., Kretzmann Filho N.A. Evaluation of the C3435T polymorphism in the MDR1 gene in patients with hepatocellular carcinoma. Ann. Hepatol. 2012, 11:899-906.
5. Balmasova I.P., Yushchuk N.D., Mynbaev O.A., Alla N.R., Malova E.S., Shi Z., Gao C.L. Immunopathogenesis of chronic hepatitis B. World J. Gastroenterol. 2014, 20:14156-14171.
6. Chemin I., Zoulim F. Hepatitis B virus induced hepatocellular carcinoma. Cancer Lett. 2009, 286:52-59.
7. Chew V., Abastado J.P. Immunomodulation of the tumor microenvironment by Toll-like receptor-3 (TLR3) ligands. Oncoimmunology 2013, 2:e23493.
8. D'Atri L.P., Etulain J., Rivadeneyra L., Lapponi M.J., Centurion M., Cheng K., Yin H., Schattner M. Expression and functionality of Toll-like receptor 3 in the megakaryocytic lineage. J. Thromb. Haemost. 2015, 13:839-850.
9. Etem E.O., Elyas H., Ozgocmen S., Yildirim A., Godekmerdan A. The investigation of toll-like receptor 3, 9 and 10 gene polymorphisms in Turkish rheumatoid arthritis patients. Rheumatol. Int. 2011, 31:1369-1374.
10. Etokebe G.E., Knezevic J., Petricevic B., Pavelic J., Vrbanec D., Dembic Z. Single-nucleotide polymorphisms in genes encoding toll-like receptor -2, -3, -4, and -9 in case-control study with breast cancer. Genet. Test. Mol. Biomarkers 2009, 13:729-734.
11. Farazi P.A., DePinho R.A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat. Rev. Cancer 2006, 6:674-687.
12. Gao Y., Guo J., Zhang F., Guo Z., Zhang L.R., Wang T., Wang B., Feng S.Y., Wang S.P. Evaluation of neonatal Toll-like receptors 3 (c.1377C/T) and 9 (G2848A) gene polymorphisms in HBV intrauterine transmission susceptibility. Epidemiol. Infect. 2014, 1-8.
13. Guo Z., Chen L., Zhu Y., Zhang Y., He S., Qin J., Tang X., Zhou J., Wei Y. Double-stranded RNA-induced TLR3 activation inhibits angiogenesis and triggers apoptosis of human hepatocellular carcinoma cells. Oncol. Rep. 2012, 27:396-402.
14. He J.F., Jia W.H., Fan Q., Zhou X.X., Qin H.D., Shugart Y.Y., Zeng Y.X. Genetic polymorphisms of TLR3 are associated with nasopharyngeal carcinoma risk in Cantonese population. BMC Cancer 2007, 7:194.
15. Ishizaki Y., Takemoto M., Kira R., Kusuhara K., Torisu H., Sakai Y., Sanefuji M., Yukaya N., Hara T. Association of toll-like receptor 3 gene polymorphism with subacute sclerosing panencephalitis. J. Neurovirol. 2008, 14:486-491.
16. Isogawa M., Robek M.D., Furuichi Y., Chisari F.V. Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J. Virol. 2005, 79:7269-7272.
17. Konig I.R., Schafer H., Muller H.H., Ziegler A. Optimized group sequential study designs for tests of genetic linkage and association in complex diseases. Am. J. Hum. Genet. 2001, 69:590-600.
18. Lee S.O., Brown R.A., Razonable R.R. Association between a functional polymorphism in Toll-like receptor 3 and chronic hepatitis C in liver transplant recipients. Transpl. Infect. Dis. 2013, 15:111-119.
19. Li G., Zheng Z. Toll-like receptor 3 genetic variants and susceptibility to hepatocellular carcinoma and HBV-related hepatocellular carcinoma. Tumour Biol. 2013, 34:1589-1594.
20. Li K., Chen Z., Kato N., Gale M., Lemon S.M. Distinct poly(I-C) and virus-activated signaling pathways leading to interferon-beta production in hepatocytes. J. Biol. Chem. 2005, 280:16739-16747.
21. Li N., Li Q., Qian Z., Zhang Y., Chen M., Shi G. Impaired TLR3/IFN-beta signaling in monocyte-derived dendritic cells from patients with acute-on-chronic hepatitis B liver failure: relevance to the severity of liver damage. Biochem. Biophys. Res. Commun. 2009, 390:630-635.
22. Li S., Deng Y., Chen Z.P., Huang S., Liao X.C., Lin L.W., Li H., Peng T., Qin X., Zhao J.M. Genetic polymorphism of interleukin-16 influences susceptibility to HBV-related hepatocellular carcinoma in a Chinese population. Infect. Genet. Evol. 2011, 11:2083-2088.
23. Liaw Y.F., Chu C.M. Hepatitis B virus infection. Lancet 2009, 373:582-592.
24. Liu C., Wang Y.M., Fan K. Epidemiological and clinical features of hepatitis B virus related liver failure in China. World J. Gastroenterol. 2011, 17:3054-3059.
25. Long H., O'Connor B.P., Zemans R.L., Zhou X., Yang I.V., Schwartz D.A. The Toll-like receptor 4 polymorphism Asp299Gly but not Thr399Ile influences TLR4 signaling and function. PLoS One 2014, 9:e93550.
26. Mandal R.K., George G.P., Mittal R.D. Association of Toll-like receptor (TLR) 2, 3 and 9 genes polymorphism with prostate cancer risk in North Indian population. Mol. Biol. Rep. 2012, 39:7263-7269.
27. Matsumoto M., Oshiumi H., Seya T. Antiviral responses induced by the TLR3 pathway. Rev. Med. Virol. 2011, 21:67-77.
28. Ming Lim C., Stephenson R., Salazar A.M., Ferris R.L. TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR head and neck cancer cells. Oncoimmunology 2013, 2:e24677.
29. Minmin S., Xiaoqian X., Hao C., Baiyong S., Xiaxing D., Junjie X., Xi Z., Jianquan Z., Songyao J. Single nucleotide polymorphisms of Toll-like receptor 4 decrease the risk of development of hepatocellular carcinoma. PLoS One 2011, 6:e19466.
30. O'Neill L.A., Bryant C.E., Doyle S.L. Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacol. Rev. 2009, 61:177-197.
31. Pandey S., Mittal B., Srivastava M., Singh S., Srivastava K., Lal P., Mittal R.D. Evaluation of Toll-like receptors 3 (c.1377C/T) and 9 (G2848A) gene polymorphisms in cervical cancer susceptibility. Mol. Biol. Rep. 2011, 38:4715-4721.
32. Rong Y., Song H., You S., Zhu B., Zang H., Zhao Y., Li Y., Wan Z., Liu H., Zhang A., Xiao L., Xin S. Association of Toll-like receptor 3 polymorphisms with chronic hepatitis B and hepatitis B-related acute-on-chronic liver failure. Inflammation 2013, 36:413-418.
33. Sato Y., Goto Y., Narita N., Hoon D.S. Cancer cells expressing Toll-like receptors and the tumor microenvironment. Cancer Microenviron. 2009, 2(Suppl. 1):205-214.
34. Seki E., Brenner D.A. Toll-like receptors and adaptor molecules in liver disease: update. Hepatology 2008, 48:322-335.
35. Shen Y., Bu M., Zhang A., Liu Y., Fu B. Toll-like receptor 4 gene polymorphism downregulates gene expression and involves in susceptibility to bladder cancer. Tumour Biol. 2015, 36:2779-2784.
36. Shi Y.Y., He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res. 2005, 15:97-98.
37. Singh V., Srivastava N., Kapoor R., Mittal R.D. Single-nucleotide polymorphisms in genes encoding toll-like receptor -2, -3, -4, and -9 in a case-control study with bladder cancer susceptibility in a North Indian population. Arch. Med. Res. 2013, 44:54-61.
38. Sironi M., Biasin M., Cagliani R., Forni D., De Luca M., Saulle I., Lo Caputo S., Mazzotta F., Macias J., Pineda J.A., Caruz A., Clerici M. A common polymorphism in TLR3 confers natural resistance to HIV-1 infection. J. Immunol. 2012, 188:818-823.
39. Testro A.G., Visvanathan K. Toll-like receptors and their role in gastrointestinal disease. J. Gastroenterol. Hepatol. 2009, 24:943-954.
40. Wang K., Liu H., He Y., Chen T., Yang Y., Niu Y., Chen H., Chen Y., Liu J., Ye F., Lin S., Zhao Y. Correlation of TLR1-10 expression in peripheral blood mononuclear cells with chronic hepatitis B and chronic hepatitis B-related liver failure. Hum. Immunol. 2010, 71:950-956.
41. Werling D., Jungi T.W. TOLL-like receptors linking innate and adaptive immune response. Vet. Immunol. Immunopathol. 2003, 91:1-12.
42. Wu J., Lu M., Meng Z., Trippler M., Broering R., Szczeponek A., Krux F., Dittmer U., Roggendorf M., Gerken G., Schlaak J.F. Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice. Hepatology 2007, 46:1769-1778.
43. Wu J., Meng Z., Jiang M., Pei R., Trippler M., Broering R., Bucchi A., Sowa J.P., Dittmer U., Yang D., Roggendorf M., Gerken G., Lu M., Schlaak J.F. Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology 2009, 49:1132-1140.
44. Yuan M.M., Xu Y.Y., Chen L., Li X.Y., Qin J., Shen Y. TLR3 expression correlates with apoptosis, proliferation and angiogenesis in hepatocellular carcinoma and predicts prognosis. BMC Cancer 2015, 15:245.
45. Zhang E., Lu M. Toll-like receptor (TLR)-mediated innate immune responses in the control of hepatitis B virus (HBV) infection. Med. Microbiol. Immunol. 2015, 204:11-20.